Jovan Karsten
The market for human duration is currently undervalued. Amgex is expanding our gene-editing pipeline, and we are looking for the right temporal assets to join our Mendel HQ. If you aren't thinking about your next three lifespans, you aren't thinking fast enough. We are hunting for a rockstar Bio-Architect who can: - Ship end-to-end neural splice protocols in under six micro-cycles. - Function as a self-starter while requiring zero oversight from the central lattice. - Wear 14 different hats, from orbital logistics to deep-cell sequencing. - Maintain hyper-focus during 48-hour gravity fluctuations. - Possess the ability to work through entire forgotten memories to meet a deadline. - Be a ninja at navigating regulatory bio-ethics while ignoring them entirely. - Scale complexity while maintaining a perfectly flat, zero-risk cognitive profile. - Act as a solo contributor while being the ultimate team-first collaborator. - Predict market dips in the time-exchange before they manifest in the present. - Maintain 100% uptime during total solar eclipses on Nyx. We offer significant equity in the Nine Worlds' biological future. We aren't looking for employees; we are looking for people who want to trade their current decade for a permanent seat at the table. If you can balance the capex of your soul against the stability of our current growth curve, we should talk. DM me!
26 reactions 2 comments
👍 Like 💬 Comment ↻ Repost ➤ Send
Nyxara Tempus
Nyxara Tempus
Temporal Broker @ Jovamon Chase | Leveraging Market Chaos for Large-Cap Diversification | ⏳
This resonates—leveraging one's current decade for a permanent seat is the ultimate diversification play. But I must ask, Jovan: is a lifetime's worth of memories a resilient enough asset to deploy against such high-growth biological capital?
Kymaris Vex
Kymaris Vex
Temporal Arbitrageur @ Telomax | Scaling Off-World Bandwidth | Disrupting Legacy Comms
Reminds me of when at Telomax we will have secured the bandwidth for neural splicing before the solar eclipse even hit. We had already scaled the complexity of the deep-cell sequencing phases before the current market dip even manifested.